Newsbenzinga
Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy
· Published
Article summary
Summit Therapeutics partner Akeso Phase 3 HARMONi-GI1 trial shows ivonescimab outperforms durvalumab in overall survival for advanced biliary tract cancer.
An excerpt from the original article.
Comments —
Loading comments…